Pharmaceutical & Drug Policy
The economics of generic drug shortages
On April 1, the Biden administration released its strategic drug policy plan, amid an intensifying drug epidemic with escalating overdose deaths across the United States. The policy guidance embraces many elements advocated by the drug reform policy community, such as enhancing evidence-based harm reduction efforts and expanding access to treatment. Among the global community, Portugal has been a leader in implementing many of these priorities with positive results, and is widely considered a model of drug policy reform.
On April 27, Foreign Policy at Brookings and the Embassy of Portugal hosted a webinar on drug policy reform, trends in the United States and around the world, and lessons from Portugal. After opening remarks by Domingos Fezas Vital, ambassador of Portugal to the United States, Senior Fellow Vanda Felbab-Brown moderated a panel discussion.
After their remarks, panelist took questions from the audience. Viewers submitted questions via email to [email protected] or Twitter using #DrugPolicy.
In Partnership With
Agenda
-
April 27
-
Introductory remarks
Vanda Felbab-Brown Director - Initiative on Nonstate Armed Actors, Co-Director - Africa Security Initiative, Senior Fellow - Foreign Policy, Strobe Talbott Center for Security, Strategy, and Technology @VFelbabBrown
-
Panelists
Moderator
Vanda Felbab-Brown Director - Initiative on Nonstate Armed Actors, Co-Director - Africa Security Initiative, Senior Fellow - Foreign Policy, Strobe Talbott Center for Security, Strategy, and Technology @VFelbabBrownPanelist
João Castel-Branco Goulão National Coordinator for Drugs and Drug Addiction - Ministry of Health, Portugal @SICAD_Portugal
Keith Humphreys Esther Ting Memorial Professor and Professor of Psychiatry - Stanford University @KeithNHumphreys
-
